ZA968382B - Vector and method of use for nucleic acid delivery to non-dividing cells - Google Patents

Vector and method of use for nucleic acid delivery to non-dividing cells

Info

Publication number
ZA968382B
ZA968382B ZA968382A ZA968382A ZA968382B ZA 968382 B ZA968382 B ZA 968382B ZA 968382 A ZA968382 A ZA 968382A ZA 968382 A ZA968382 A ZA 968382A ZA 968382 B ZA968382 B ZA 968382B
Authority
ZA
South Africa
Prior art keywords
vector
dividing cells
nucleic acid
acid delivery
disorders
Prior art date
Application number
ZA968382A
Other languages
English (en)
Inventor
Inder Verma
Didier Trono
Luigi Naldini
Philippe Gallay
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24154683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA968382(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Publication of ZA968382B publication Critical patent/ZA968382B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA968382A 1995-10-06 1996-10-04 Vector and method of use for nucleic acid delivery to non-dividing cells ZA968382B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/540,259 US6013516A (en) 1995-10-06 1995-10-06 Vector and method of use for nucleic acid delivery to non-dividing cells

Publications (1)

Publication Number Publication Date
ZA968382B true ZA968382B (en) 1997-06-27

Family

ID=24154683

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA968382A ZA968382B (en) 1995-10-06 1996-10-04 Vector and method of use for nucleic acid delivery to non-dividing cells

Country Status (9)

Country Link
US (1) US6013516A (enExample)
EP (1) EP0871459B1 (enExample)
JP (1) JP4190579B2 (enExample)
AT (1) ATE260981T1 (enExample)
AU (1) AU720993B2 (enExample)
DE (1) DE69631795T2 (enExample)
IL (1) IL123833A0 (enExample)
WO (1) WO1997012622A1 (enExample)
ZA (1) ZA968382B (enExample)

Families Citing this family (790)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
GB2325003B (en) 1996-10-17 2000-05-10 Oxford Biomedica Ltd Rectroviral vectors
US7198784B2 (en) * 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
EP0981636B1 (en) * 1997-05-13 2005-03-23 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
EP1003894A2 (en) * 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
JP4303418B2 (ja) * 1997-10-24 2009-07-29 ライフ テクノロジーズ コーポレーション 組換え部位を有する核酸を使用する組換えクローニング
EP1039931B1 (en) * 1997-12-01 2005-04-27 Fang Fang Multivalent recombinant antibodies for treating hrv infections
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1037669A4 (en) * 1997-12-12 2003-04-02 Cell Genesys Inc THERAPEUTIC USE OF LENTIVIRAL VECTORS
ATE528405T1 (de) * 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6451304B1 (en) * 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
AU2007216712B2 (en) * 1998-04-24 2010-05-27 Centre National De La Recherche Scientifique Use of Triplex Structure DNA Sequences for Transferring Nucleotide Sequences
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
AU2003271326B2 (en) * 1998-04-24 2007-06-28 Centre National De La Recherche Scientifique Use of triplex structure DNA sequences for transferring nucleotide sequences
US6365150B1 (en) 1998-05-13 2002-04-02 Genetix Pharmaceuticals, Inc. Lentiviral packaging cells
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6790657B1 (en) * 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
WO2000046377A1 (en) * 1999-02-02 2000-08-10 Thomas Jefferson University Genetically engineered retroviral vector particles capable of infecting non-dividing cells
AU778698B2 (en) * 1999-04-29 2004-12-16 Miltenyi Biotec B.V. & Co. KG Method and means for producing high titer, safe, recombinant lentivirus vectors
AU5250100A (en) * 1999-06-22 2001-01-09 Dnavec Research Inc. Vector for expressing two foreign genes
EP2169073B1 (en) * 1999-10-11 2013-11-13 Institut Pasteur Vector for the preparation of immunotherapeutical compositions
WO2001027304A2 (en) 1999-10-12 2001-04-19 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1103615A1 (en) * 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US6864085B2 (en) * 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
WO2001044458A2 (en) * 1999-12-14 2001-06-21 Novartis Ag Bovine immunodeficiency virus (biv) based vectors
CN102151337B (zh) 2000-03-13 2014-03-12 恩根尼公司 调节消化道蛋白表达的组合物和方法
US20040102388A1 (en) * 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
CA2410015A1 (en) * 2000-05-26 2001-12-06 Thomas W. Dubensky, Jr. Methods of transducing neural cells using lentivirus vectors
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CA2413156C (en) * 2000-07-03 2009-08-18 Gala Design, Inc. Expression vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
EP1472337A4 (en) 2001-03-09 2008-02-27 Univ Texas INDUCTION OF TUMORIMMUNITY BY VARIATIONS OF THE FOLAT BINDING PROTEIN
AU2002254212A1 (en) * 2001-03-12 2002-09-24 Irm, Llc Identification of cellular targets for biologically active molecules
US20040076954A1 (en) * 2001-03-12 2004-04-22 Irm, Llc Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
ATE541937T1 (de) * 2001-04-06 2012-02-15 Univ Chicago Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
EP1395293B1 (en) * 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
WO2002095002A2 (en) 2001-05-22 2002-11-28 University Of Chicago N4 virion single-stranded dna dependent rna polymerase
US7381813B2 (en) 2001-05-31 2008-06-03 Novartis Ag Nucleic acids encoding estrogen receptor ligand binding domain variants
IL159371A0 (en) 2001-06-29 2004-06-01 Sloan Kettering Inst Cancer Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
WO2003012054A2 (en) * 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
AU2002327430A1 (en) * 2001-08-08 2003-02-24 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
WO2003022228A2 (en) * 2001-09-13 2003-03-20 California Institute Of Technology Method for producing transgenic birds and fish
AU2002326906C1 (en) 2001-09-13 2009-01-29 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
CN1612931A (zh) 2002-01-09 2005-05-04 米诺斯生物系统有限公司 遗传操作方法
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
DE10215123A1 (de) * 2002-04-05 2003-10-16 Klaus Cichutek Von SIVsmmPBj14 abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
DK1499736T3 (da) 2002-04-26 2009-06-08 Inst Nat Sante Rech Med Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer
US6863884B2 (en) * 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
WO2003093417A2 (en) 2002-05-01 2003-11-13 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
AU2002344959A1 (en) * 2002-05-03 2003-11-17 Nikolai Rainov Use of fasl for the treatment of neurodegenerative diseases
EP1997913A1 (en) 2002-05-15 2008-12-03 Integragen Human obesity susceptibility gene and uses thereof
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
US20040009158A1 (en) * 2002-07-11 2004-01-15 Washington University Promotion of neovascularization using bone marrow-derived endothelial-progenitor cells
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
AU2003291426A1 (en) * 2002-11-12 2004-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Human Services, The National Institutes Of Health Gp64-pseudotyped vectors and uses thereof
DK1563069T3 (da) * 2002-11-22 2012-07-23 Inst Clayton De La Rech Sammensætninger og systemer til genregulering
DK1616012T3 (da) 2003-04-24 2008-04-21 San Raffaele Centro Fond Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf
US20050036988A1 (en) * 2003-05-28 2005-02-17 Ruian Xu Compositions and methods for preventing and treating liver cirrhosis
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
JP2007503210A (ja) 2003-08-22 2007-02-22 アンテグラジャン ヒト自閉症感受性遺伝子およびその使用
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
US8304189B2 (en) * 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
WO2005056761A2 (en) * 2003-12-05 2005-06-23 Massachusetts Institute Of Technology REAGENTS AND METHODS FOR IDENTIFICATION OF RNAi PATHWAY GENES AND CHEMICAL MODULATORS OF RNAi
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
US20060058255A1 (en) * 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
WO2005086967A2 (en) * 2004-03-11 2005-09-22 Shantha West, Inc. Therapeutic use of rm1 antigen
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
CN1980955A (zh) * 2004-04-29 2007-06-13 北卡罗来纳-查佩尔山大学 增强细胞粘连特性的方法和组合物
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US20080193464A1 (en) 2004-07-01 2008-08-14 Anne Philippi Human Autism Susceptibility Gene Encoding Prkcb1 and Uses Thereof
US7862829B2 (en) * 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
WO2006017279A2 (en) * 2004-07-12 2006-02-16 Board Of Regents, The University Of Texas System Methods and compositions related to identifying protein-protein interactions
EP1781284B1 (en) * 2004-08-25 2010-10-13 The University of Chicago Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
JP2008525000A (ja) * 2004-12-28 2008-07-17 アレス トレーディング エス．エー． 統合失調症及び関連障害を治療するための組成物及び方法
WO2007046839A2 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
MX2007010008A (es) 2005-02-16 2008-01-18 Lentigen Corp Vectores lentivirales y su uso.
DE602006017045D1 (de) 2005-03-24 2010-11-04 Integragen Sa Ein transmembranprotein kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
US20090203055A1 (en) * 2005-04-18 2009-08-13 Massachusetts Institute Of Technology Compositions and methods for RNA interference with sialidase expression and uses thereof
WO2006127585A2 (en) * 2005-05-20 2006-11-30 Virxsys Corporation Transduction of primary cells
CA2611056C (en) 2005-06-01 2016-06-28 California Institute Of Technology Method of targeted gene delivery using viral vectors
EP1739092A1 (en) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
WO2007044627A2 (en) * 2005-10-06 2007-04-19 Sloan Kettering Institute For Cancer Research Compositions and methods for delivery of interfering rna
ES2380803T3 (es) 2005-11-14 2012-05-18 Centre National De La Recherche Scientifique (Cnrs) Dominio no histona MACROH2A como inhibidor de la actividad PARP-1 y uso del mismo
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
MX361816B (es) 2006-02-09 2018-12-17 Genzyme Corp Suministro intraventricular lento.
EP1835032A1 (en) 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
EP1835036A1 (en) 2006-03-16 2007-09-19 Exonhit Therapeutics SA Methods and compositions for the detection and treatment of cancers
US20070248539A1 (en) * 2006-04-24 2007-10-25 Shantha West Inc. AgRM2 antigen
BRPI0714495B8 (pt) 2006-07-21 2021-05-25 California Inst Of Techn lentivírus deficiente para replicação recombinante pseudotipado
WO2008013692A2 (en) 2006-07-25 2008-01-31 Celladon Corporation Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
EP2069791B1 (en) 2006-07-27 2012-01-25 University of Maryland, Baltimore Cellular receptor for antiproliferative factor
US8685720B2 (en) * 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
WO2008152446A2 (en) 2006-11-27 2008-12-18 Patrys Limited Novel glycosylated peptide target in neoplastic cells
US20080292591A1 (en) * 2007-03-05 2008-11-27 The Salk Institute For Biological Studies Tumor mouse models using lentiviral vectors
DK2170938T3 (da) * 2007-06-06 2012-07-16 Res Dev Foundation RTEF-1-varianter samt deres anvendelse til inhibering af angiogenese
EP2185694A2 (en) 2007-08-02 2010-05-19 California Stem Cell, Inc. Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells
EP2027868A1 (en) 2007-08-24 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of SCO-Spondin peptides for inhibiting or preventing neuronal apoptosis mediated by cell death receptor ligands
US9593340B2 (en) * 2007-10-15 2017-03-14 Admedus Vaccines Pty Ltd. Expression system for modulating an immune response
US9605035B2 (en) 2008-01-10 2017-03-28 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
WO2009094647A2 (en) 2008-01-25 2009-07-30 Introgen Therapeutics, Inc. P53 biomarkers
US20100303828A1 (en) 2008-01-31 2010-12-02 INSERM Institut National de la Sante et de la Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
EP2282759B1 (en) * 2008-04-30 2015-09-16 KCI Licensing, Inc. Use of nucleic acids with reduced pressure therapy for treating wounds
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
CA2734325A1 (en) 2008-08-18 2010-02-25 University Of Maryland, Baltimore Derivatives of apf and methods of use
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
US8211487B2 (en) * 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
JP6093110B2 (ja) 2008-12-17 2017-03-08 ザ スクリプス リサーチ インスティテュート 幹細胞の作製と維持
EP2199387A1 (en) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses for the prevention and/or the treatment of blood coagulation disorders
ES2629099T3 (es) 2008-12-19 2017-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de serin proteasa y usos en la prevención o el tratamiento de y trastornos de la coagulación sanguinea
EP3002296B1 (en) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
DK2424885T3 (en) 2009-04-28 2016-06-06 Univ Vanderbilt Compositions and methods for the treatment of disorders involving epitelcelleapoptose
EP2427205A2 (en) 2009-05-04 2012-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Par2 agonists for use in the treatment or prevention of influenza virus type a infections
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
AU2010274031B2 (en) 2009-07-15 2015-07-16 Csl Behring Gene Therapy, Inc. Dual vector for inhibition of human immunodeficiency virus
KR101790187B1 (ko) 2009-07-24 2017-10-25 이뮨 디자인 코포레이션 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터
KR101574056B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
KR20210054598A (ko) 2009-09-21 2021-05-13 다케다 야쿠힌 고교 가부시키가이샤 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
US9005968B2 (en) 2009-10-16 2015-04-14 The Scripps Research Institute Induction of pluripotent cells
WO2011048443A1 (en) 2009-10-20 2011-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal exocytosis inhibiting peptides derived from c subunit of v-atpase and cosmetic and pharmaceutical compositions containing said peptides
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
WO2011080322A1 (en) 2009-12-30 2011-07-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
CA2786664C (en) 2010-01-08 2020-03-10 Immusoft Corporation Vectors and methods for transducing b cells
EP2524226A1 (en) 2010-01-13 2012-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Promyelocytic leukemia protein as a redox sensor
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
HUE050815T2 (hu) 2010-04-08 2021-01-28 Inst Nat Sante Rech Med A trem-szerû 1. transzkriptumból (tlt-1) származó gátló peptidek és azok felhasználása
WO2011133512A1 (en) 2010-04-19 2011-10-27 Research Development Foundation Rtef-1 variants and uses thereof
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2011147889A1 (en) 2010-05-25 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
CA2802087A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. A compendium of ready-built stem cell models for interrogation of biological response
WO2012006440A2 (en) 2010-07-07 2012-01-12 Cellular Dynamics International, Inc. Endothelial cell production by programming
PT3626736T (pt) 2010-07-08 2025-08-11 Takeda Pharmaceuticals Co Método de produção de fvw recombinante de elevado peso molecular na cultura celular
WO2012004416A2 (en) 2010-07-09 2012-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of a disease associated with retinal degenerative disorder
EP2596025B1 (en) 2010-07-23 2018-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
KR101990068B1 (ko) * 2010-09-02 2019-06-17 몰메드 에스피에이 렌티바이러스 벡터의 안정한 제조
US9132173B2 (en) 2010-10-15 2015-09-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
AU2011349446C1 (en) 2010-12-22 2016-01-21 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
US9598499B2 (en) 2010-12-30 2017-03-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antigen binding formats for use in therapeutic treatments or diagnostic assays
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
EP2741784B1 (en) 2011-03-02 2017-05-17 Board Of Regents, The University Of Texas System Tusc2 therapies
WO2012120131A1 (en) 2011-03-09 2012-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for generating cell microparticles
WO2012120129A1 (en) 2011-03-10 2012-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
MX373443B (es) 2011-03-31 2020-05-20 Inst Nat Sante Rech Med Anticuerpos dirigidos contra icos y usos de los mismos.
US9346883B2 (en) 2011-05-13 2016-05-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies against HER3
JP2014516960A (ja) 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
WO2012156535A1 (en) 2011-05-19 2012-11-22 Fundación Progreso Y Salud Highly inducible dual-promoter lentiviral tet-on system
AU2012267512B2 (en) 2011-06-10 2014-11-20 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
EP2721057B1 (en) 2011-06-15 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
WO2013009825A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
FR2979346B1 (fr) 2011-08-23 2013-09-27 Univ Joseph Fourier Nanocorps anti-vcam-1
US20140235492A1 (en) 2011-09-20 2014-08-21 Institut National De La Sante Et De La Recherche Medicate (Inserm) Methods for preparing single domain antibody microarrays
JP6066356B2 (ja) 2011-09-23 2017-01-25 ブルーバード バイオ， インコーポレイテッド 改善された遺伝子治療方法
EP3269802B1 (en) 2011-09-30 2019-10-23 Bluebird Bio, Inc. Compounds for improved viral transduction
BR112014010091B1 (pt) 2011-10-27 2022-11-08 Wellstat Ophthalmics Corporation Ácido nucleico, vetor viral, preparação farmacêutica, uso destes, método para produção de uma proteína rdcvf, e método in vitro ou ex vivo de secreção de uma proteína rdcvf a partir de uma célula
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
WO2013162748A1 (en) 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2013174835A1 (en) 2012-05-22 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening a candidate compound for its pharmacology on a nuclear receptor
EP2855678B1 (en) 2012-05-25 2017-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for selecting binders by phage display and masked selection
DK2855665T3 (da) 2012-05-30 2019-11-04 Univ Cornell Tilvejebringelse af funktionelle og bestandige endotele celler fra humane amnionvæske-afledte celler
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
WO2014022455A1 (en) 2012-07-31 2014-02-06 The Board Of Regents Of The University Of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation
EP2692732A1 (en) 2012-08-03 2014-02-05 Stallergenes S.A. Novel allergen from ragweed pollen and uses thereof
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
ES2797625T3 (es) 2012-09-07 2020-12-03 Inst Nat Sante Rech Med Péptidos inhibitorios derivados del receptor desencadenante expresado en células mieloides-1 (TREM-1) y del transcrito similar a TREM 1 (TLT-1) y sus usos
AU2013328550B2 (en) 2012-10-12 2017-10-05 University Of Leicester CSN5 polypeptides and uses thereof for screening therapeutic agents
US9593365B2 (en) 2012-10-17 2017-03-14 Spatial Transcriptions Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
HRP20170743T1 (hr) 2012-11-20 2017-07-28 Sanofi Anti-ceacam5 protutijela i njihova uporaba
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP2749289A1 (en) 2012-12-26 2014-07-02 Institut National De La Recherche Agronomique (INRA) Anti-inflammatory peptides
US11013783B2 (en) 2012-12-26 2021-05-25 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Anti-inflammatory peptides and methods for treating inflammatory diseases
EP3400961B1 (en) 2012-12-27 2021-02-24 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
EP2953970A4 (en) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
CN105229144A (zh) 2013-02-22 2016-01-06 细胞动力学国际有限公司 通过组合的遗传工程和化学工程经由正向编程产生肝细胞
US20160010094A1 (en) 2013-03-01 2016-01-14 University Of Pretoria Transgenic cell selection
HK1220111A1 (zh) 2013-03-05 2017-04-28 Baylor College Of Medicine 人类t淋巴细胞中类肝素酶的表达
JP6420776B2 (ja) 2013-03-05 2018-11-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫療法のためのエンゲージャー細胞
EP3241897B1 (en) 2013-03-07 2018-10-03 Baylor College of Medicine Targeting cd138 in cancer
HK1219980A1 (zh) 2013-03-09 2017-04-21 Baylor College Of Medicine 靶向血管的t细胞疗法
JP6392315B2 (ja) 2013-03-14 2018-09-19 イミュソフト コーポレーション インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
DK3013983T3 (da) 2013-06-25 2023-03-06 Prognosys Biosciences Inc Spatialt kodede biologiske assays ved brug af en mikrofluidisk anordning
US20160152952A1 (en) 2013-06-25 2016-06-02 Temple University-Of The Commonwealth System Of Higher Education Cortical Bone-Derived Stem Cells
ES2698375T3 (es) 2013-06-27 2019-02-04 Inst Nat Sante Rech Med Antagonistas de interleucina 15 (IL-15) y usos de los mismos para el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
US11819555B2 (en) 2013-09-09 2023-11-21 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
EP3065711B8 (en) 2013-11-05 2024-10-16 Takara Bio USA, Inc. Dry transfection compositions and methods for making and using the same
WO2015067668A1 (en) 2013-11-05 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) New alzheimer's disease animal model
CA2929386C (en) 2013-11-07 2023-01-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody
EP3065775B1 (en) 2013-11-08 2020-09-30 The Board of Regents of the University of Texas System Vh4 antibodies against gray matter neuron and astrocyte
US10028902B2 (en) 2013-11-08 2018-07-24 Baylor Research Institute Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
EP3074025A1 (en) 2013-11-27 2016-10-05 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
KR20160108540A (ko) 2014-01-20 2016-09-19 사노피 증가된 효소 활성을 갖는 신규한 시토크롬 p450 폴리펩티드
MX380864B (es) 2014-01-29 2025-03-12 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
EP3110836A1 (en) 2014-02-25 2017-01-04 Research Development Foundation Sty peptides for inhibition of angiogenesis
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
WO2015158851A1 (en) 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
WO2015158810A1 (en) 2014-04-17 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
IL296691B2 (en) 2014-04-25 2023-11-01 2Seventy Bio Inc MND promoter chimeric antigen receptors
EP3738597A1 (en) 2014-04-25 2020-11-18 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
CN106793780B (zh) 2014-06-06 2020-05-26 蓝鸟生物公司 改善的t细胞组合物
EP2957634A1 (en) 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
EP2974735A1 (en) 2014-07-15 2016-01-20 Institut National De La Recherche Agronomique (INRA) Anti-inflammatory properties of a surface protein of propionibacterium freudenreichii
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EP2977463A1 (en) 2014-07-25 2016-01-27 Centro de Investigación Biomédica en Red (CIBER) Methods and agents related to lung diseases
EP3188762A4 (en) 2014-07-31 2018-01-10 The Board of Regents of the University of Oklahoma High isomerohydrolase activity mutants of mammalian rpe65
WO2016025510A1 (en) 2014-08-12 2016-02-18 Rappolee Daniel A Systems and methods to detect stem cell stress and uses thereof
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
WO2016030501A1 (en) 2014-08-28 2016-03-03 Centre National De La Recherche Scientifique - Cnrs - Synthetic alu-retrotransposon vectors for gene therapy
EP3189152A4 (en) 2014-09-03 2018-04-04 BioAtla LLC Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
DK3194602T3 (da) 2014-09-18 2020-02-17 Univ Montreal Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler
EP3858991A1 (en) 2014-09-26 2021-08-04 Baylor College of Medicine Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
EP3971210A1 (en) 2014-12-12 2022-03-23 2seventy bio, Inc. Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
RU2017125735A (ru) 2014-12-19 2019-01-22 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы против карбоангидразы ix и способы их применения
KR102923234B1 (ko) 2014-12-19 2026-02-04 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
EP4177336A1 (en) 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
EP3812398A3 (en) 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MA41433A (fr) 2015-01-26 2017-12-05 Baylor College Medicine Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
CN107531780B (zh) 2015-02-03 2021-11-02 国家健康与医学研究院 抗-Rho GTPase的构象单域抗体及其用途
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
WO2016134293A1 (en) 2015-02-20 2016-08-25 Baylor College Of Medicine p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP7095994B2 (ja) 2015-03-02 2022-07-05 アドヴェラム バイオテクノロジーズ， インコーポレイテッド ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
WO2016150964A1 (en) 2015-03-23 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia
EP3286225B1 (en) 2015-04-23 2020-07-01 Baylor College of Medicine Cd5 chimeric antigen receptor for adoptive t cell therapy
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
WO2016186708A1 (en) 2015-05-18 2016-11-24 Calimmune, Inc. Gene therapeutic for the treatment of hiv and uses thereof
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
US20180125947A1 (en) 2015-05-20 2018-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of retinal detachment
EP3685830A1 (en) 2015-05-20 2020-07-29 Institut National De La Sante Et De La Recherche Medicale - Inserm Methods and pharmaceutical composition for modulation polarization and activation of macrophages
WO2016188911A1 (en) 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
WO2017004579A1 (en) 2015-07-01 2017-01-05 O'connor Colleen M Artificial antigen presenting cells for adoptive cell therapy against cancer
WO2017005847A1 (en) 2015-07-07 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to myosin 18a and uses thereof
AU2016309948B2 (en) 2015-08-14 2021-05-20 The University Of Sydney Connexin 45 inhibition for therapy
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
ES2911015T3 (es) 2015-08-31 2022-05-17 Helixmith Co Ltd Receptores quiméricos de antígeno anti-sialil Tn
JP6800219B2 (ja) 2015-09-16 2020-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用
US10647752B2 (en) 2015-09-22 2020-05-12 Inserm (Institut National De La Santé Et De La Recherche Medicale) Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1
WO2017050955A1 (en) 2015-09-24 2017-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Agents capable of inhibiting the binding between leptin and vegf165
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
CA3001917A1 (en) 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
ES2862676T3 (es) 2015-10-20 2021-10-07 Fujifilm Cellular Dynamics Inc Producción de células precursoras hematopoyéticas multilinaje mediante programación genética
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
WO2017079202A1 (en) 2015-11-02 2017-05-11 Board Of Regents, The University Of Texas System Methods of cd40 activation and immune checkpoint blockade
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN116479001A (zh) 2015-11-13 2023-07-25 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
TWI823830B (zh) 2015-11-13 2023-12-01 日商武田藥品工業股份有限公司 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
WO2017096363A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Reporter system for detecting and targeting activated cells
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
CA3006779A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
PL3405215T3 (pl) 2016-01-19 2022-10-31 The Regents Of The University Of California Sposoby leczenia choroby danona i innych zaburzeń autofagii
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
EP3413896B1 (en) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
RU2021103425A (ru) 2016-02-12 2021-02-25 Блубёрд Био, Инк. Композиции, повышающие число копий вектора (чкв), и способы их применения
CA3013479A1 (en) 2016-02-16 2017-08-24 Carl NOVINA Immunotherapy compositions and methods
US20190160098A1 (en) 2016-02-16 2019-05-30 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
US10435682B2 (en) 2016-02-19 2019-10-08 University Of South Florida Arginine deiminase gene therapy for disordered proteins
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
WO2017162678A1 (en) 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
EP3436049B1 (en) 2016-03-31 2022-01-12 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
WO2017180713A1 (en) 2016-04-13 2017-10-19 Orimabs Ltd. Anti-psma antibodies and use thereof
WO2017180993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
CN109641063B (zh) 2016-04-20 2022-11-15 能源环境和技术研究中心O.A., M.P. 用于增强pklr的基因表达的组合物和方法
WO2017182608A1 (en) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions for the treatment of b-cell malignancies
WO2017182609A1 (en) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
TWI851939B (zh) 2016-05-13 2024-08-11 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CA3031994A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus
US11186634B2 (en) 2016-07-29 2021-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies targeting tumor associated macrophages and uses thereof
US11866733B2 (en) 2016-08-01 2024-01-09 University of Pittsburgh—of the Commonwealth System of Higher Education Human induced pluripotent stem cells for high efficiency genetic engineering
WO2018035141A1 (en) 2016-08-16 2018-02-22 Bluebird Bio, Inc. Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
CA3034782A1 (en) 2016-08-23 2018-03-01 Bluebird Bio, Inc. Tim3 homing endonuclease variants, compositions, and methods of use
SG11201901642XA (en) 2016-08-26 2019-03-28 Baylor College Medicine Constitutively active cytokine receptors for cell therapy
BR112019004629A2 (pt) 2016-09-08 2019-10-01 Bluebird Bio, Inc. variantes de endonuclease de homing pd-1, composições e métodos de uso
EP3512540A1 (en) 2016-09-14 2019-07-24 Université Catholique de Louvain Modified vsv-g and vaccines thereof
AU2017338846B2 (en) 2016-10-04 2020-09-24 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
ES2907741T3 (es) 2016-10-05 2022-04-26 Inst Nat Sante Rech Med Polipéptidos de elabela (ELA) para uso en el tratamiento del cáncer de riñón
KR102598351B1 (ko) 2016-10-05 2023-11-08 후지필름 셀룰러 다이내믹스, 인코포레이티드 만능 줄기 세포를 hla 동형 접합 면역 세포로 직접 분화시키기 위한 방법
EP3523422B1 (en) 2016-10-05 2024-12-25 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
WO2018069422A1 (en) 2016-10-12 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non-alcoholic fatty liver disease
CA3040458A1 (en) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Methods and compositions for tusc2 immunotherapy
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
MA46543A (fr) 2016-10-17 2019-08-21 Bluebird Bio Inc Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
CN110121508A (zh) 2016-10-25 2019-08-13 法国国家健康和医学研究院 与cd160跨膜同种型结合的单克隆抗体
FR3058143B1 (fr) 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
KR20240005168A (ko) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포 조성물
KR102431830B1 (ko) 2016-11-07 2022-08-16 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
US11116852B2 (en) 2016-11-09 2021-09-14 Precigen, Inc. Frataxin expression constructs
DK3541833T5 (da) 2016-11-17 2024-09-02 2Seventy Bio Inc TGFß signalkonverter
EP3541830A1 (en) 2016-11-17 2019-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for increasing endogenous protein level
MA46998A (fr) 2016-12-05 2019-10-09 Juno Therapeutics Inc Production de cellules modifiées pour une thérapie cellulaire adoptive
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
WO2018130518A1 (en) 2017-01-10 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inducing senescence in cancer cells
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7618386B2 (ja) 2017-01-30 2025-01-21 ブレインヴェクティス ポリグルタミン反復脊髄小脳失調症の処置におけるコレステロール２４－ヒドロキシラーゼ（ｈｙｄｒｏｌａｓｅ）のための発現ベクター
JP2020506695A (ja) 2017-01-30 2020-03-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 糖原病を処置するための組換えウイルスベクター
CN116693695A (zh) 2017-02-12 2023-09-05 百欧恩泰美国公司 基于hla的方法和组合物及其用途
EP3583201B1 (en) 2017-02-14 2024-01-17 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
AU2018221730B2 (en) 2017-02-15 2024-06-20 Novo Nordisk A/S Donor repair templates multiplex genome editing
EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
CN110831961B (zh) 2017-03-03 2024-01-02 黑曜石疗法公司 用于免疫疗法的cd19组合物和方法
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
EP3600447A4 (en) 2017-03-20 2020-12-30 Baylor College of Medicine TRANSGENIC C-MPL TO INTRODUCE LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS INTO GENETICALLY MODIFIED CELLS BY TCR
WO2018178051A1 (en) 2017-03-28 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Scgb1a1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction
EP3600355B1 (en) 2017-03-28 2025-11-05 The Trustees of the University of Pennsylvania Hla-a2 specific car for use in the treatment of transplanted tissue from rejection
EP3388072A1 (en) 2017-04-10 2018-10-17 Universität Leipzig Ubiquinone-independent cytoplasmic dihydroorotate dehydrogenase for use as medicament
EP3388520A1 (en) 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
AU2018254442B2 (en) 2017-04-18 2024-03-28 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
WO2018204694A1 (en) 2017-05-03 2018-11-08 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells.
CA3062698A1 (en) 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
WO2018213679A1 (en) 2017-05-19 2018-11-22 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
KR102386890B1 (ko) 2017-05-22 2022-04-15 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
EP3630962A4 (en) 2017-05-25 2021-01-20 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
JP7402503B2 (ja) 2017-06-14 2023-12-21 テクニスチェ ユニベルシタト ドレスデン デザイナーｄｎａ組換え酵素を利用したゲノムを遺伝的に改変するための方法及び手段
WO2018232372A1 (en) 2017-06-16 2018-12-20 Protelica, Inc. Fibronectin binding domain chimeric antigen receptors and methods of use thereof
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
CA3067416A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies for treating cancers
CN111344011B (zh) 2017-06-27 2024-01-26 纽洛可科学有限公司 抗fam19a5抗体用于治疗纤维化的用途
JP6904616B2 (ja) 2017-06-27 2021-07-21 ニューラクル サイエンス カンパニー リミテッド 緑内障治療のための配列相同性を有するファミリー、メンバーａ５抗体の用途
JP2020529834A (ja) 2017-06-30 2020-10-15 プレシジョン バイオサイエンシズ，インク． Ｔ細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変ｔ細胞
US11597917B2 (en) 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
BR112020001059A2 (pt) 2017-07-18 2020-07-14 Calimmune, Inc. composições e métodos para o tratamento de beta-hemoglobinopatias
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
KR20200064060A (ko) 2017-07-29 2020-06-05 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 세포 증폭용 시약
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
AU2018322482B2 (en) 2017-08-22 2024-04-04 Monash University Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (RAGE)
WO2019038420A1 (en) 2017-08-25 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES
JP7330174B2 (ja) 2017-09-20 2023-08-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル オートファジーをモジュレーションするための方法及び医薬組成物
AU2018335955B2 (en) 2017-09-21 2024-12-12 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for BTN2 and uses thereof
US11579147B2 (en) 2017-09-25 2023-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of VNN1 as a biomarker and a therapeutic target in sarcomas
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
WO2019070974A1 (en) 2017-10-04 2019-04-11 Bluebird Bio, Inc. PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
SG11202002263TA (en) 2017-10-16 2020-04-29 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency
MA50859A (fr) 2017-11-01 2020-09-09 Celgene Corp Procédé pour la production d'une composition de lymphocytes t
MA50855A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Procédé de génération de compositions thérapeutiques de cellules modifiées
WO2019094835A1 (en) 2017-11-10 2019-05-16 Juno Therapeutics, Inc. Closed-system cryogenic vessels
JP7433230B2 (ja) 2017-12-08 2024-02-19 ジュノー セラピューティクス インコーポレイテッド 細胞を培養するための無血清培地配合物およびその使用の方法
EP3720480A2 (en) 2017-12-08 2020-10-14 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
WO2019152747A1 (en) 2018-01-31 2019-08-08 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
WO2019178356A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Engineered cells, t cell immune modulating antibodies and methods for using the same
CN111936617A (zh) 2018-03-16 2020-11-13 益缪索夫特公司 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
WO2019186274A2 (en) 2018-03-30 2019-10-03 University Of Geneva Micro rna expression constructs and uses thereof
US12103972B2 (en) 2018-04-06 2024-10-01 Dana-Farber Cancer Institute, Inc. KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
JP7576754B2 (ja) 2018-04-11 2024-11-01 スペースクラフト セブン リミテッド ライアビリティ カンパニー 幹細胞移植のための組成物および方法
CN112262214A (zh) 2018-04-12 2021-01-22 优莫佳生物制药股份有限公司 病毒载体及包装细胞系
AU2019259798A1 (en) 2018-04-24 2020-11-12 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
AU2019261646A1 (en) 2018-04-27 2020-11-12 Spacecraft Seven, Llc Gene therapy for CNS degeneration
US12239693B2 (en) 2018-04-27 2025-03-04 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
MX2020012295A (es) 2018-05-15 2021-03-31 Flagship Pioneering Innovations V Inc Composiciones de fusosoma y usos de estas.
US12343397B2 (en) 2018-05-17 2025-07-01 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
DK3806903T5 (da) 2018-06-14 2024-08-19 2Seventy Bio Inc Cd79a kimæriske antigenreceptorer
WO2019238934A1 (en) 2018-06-15 2019-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the apolipoprotein m for the treatment and diagnosis of insulin resistance
AU2019289646B2 (en) 2018-06-18 2025-10-23 Innate Pharma Compositions and methods for treating cancer
CN119930818A (zh) 2018-06-29 2025-05-06 爱必泰生物有限公司 抗l1cam抗体及其用途
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
CN112689516A (zh) 2018-07-11 2021-04-20 细胞基因公司 抗bcma嵌合抗原受体的用途
WO2020014523A1 (en) 2018-07-12 2020-01-16 Rocket Pharmaceuticals, Ltd. Gene therapy vectors for treatment of danon disease
KR20210034013A (ko) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
KR102944997B1 (ko) 2018-08-24 2026-03-30 씨에스엘 베링 진 테라피, 인크. 무혈청 배지에서 벡터 제조
WO2020047467A2 (en) 2018-08-30 2020-03-05 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ascl1
KR20210055725A (ko) 2018-09-06 2021-05-17 상뜨로 레옹 베라르 항암 백신을 위한 공유된 종양 항원으로서 herv-k-유래된 항원
WO2020064907A1 (en) 2018-09-27 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition reducing skin inflammation
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
AU2019363368A1 (en) 2018-10-16 2021-05-13 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP3873511B1 (en) 2018-10-29 2022-12-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
WO2020102485A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
WO2020106992A1 (en) 2018-11-21 2020-05-28 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
AU2019387566A1 (en) 2018-11-30 2021-06-17 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
SG11202105380RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
WO2020117910A1 (en) 2018-12-04 2020-06-11 Catalent Pharma Solutions, Llc Vectors for protein manufacture
BR112021010047A2 (pt) 2018-12-06 2021-08-24 Bioverativ Therapeutics Inc. Uso de vetores lentivirais expressando o fator ix
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
AU2019395334B2 (en) 2018-12-10 2026-04-23 Regeneron Pharmaceuticals, Inc. PDCD-1 homing endonuclease variants
US12404500B2 (en) 2018-12-10 2025-09-02 Novo Nordisk A/S Homing endonuclease variants
EP3895052A4 (en) 2018-12-14 2022-10-26 2seventy bio, Inc. DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
JP2022514954A (ja) 2018-12-23 2022-02-16 シーエスエル・ベーリング・エルエルシー キルスイッチを有するドナーｔ細胞
EP3897745A1 (en) 2018-12-23 2021-10-27 CSL Behring LLC Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome
JP7239216B2 (ja) 2018-12-27 2023-03-14 ニューラクル サイエンス カンパニー リミテッド 粥状硬化症を治療するための抗ｆａｍ１９ａ５抗体の使用
CN113195533B (zh) 2019-01-02 2024-04-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
KR20210121077A (ko) 2019-01-15 2021-10-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US11596671B2 (en) 2019-02-01 2023-03-07 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
AU2020243076A1 (en) 2019-03-20 2021-10-14 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for BTN2 and uses thereof
WO2020193441A1 (en) 2019-03-22 2020-10-01 Université de Paris New inhibitors of lrrk2/pp1 interaction
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
JP7654557B2 (ja) 2019-03-27 2025-04-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
WO2020205889A1 (en) 2019-04-01 2020-10-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
MX2021013588A (es) 2019-05-08 2022-02-11 Medigene Immunotherapies Gmbh Células t genomodificadas.
US20220251232A1 (en) 2019-05-20 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
US20220233654A1 (en) 2019-05-21 2022-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
MX2021015125A (es) 2019-06-07 2022-04-06 Juno Therapeutics Inc Cultivo automatizado de celulas t.
US20220249637A1 (en) 2019-06-12 2022-08-11 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
WO2020254619A1 (en) 2019-06-20 2020-12-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- protease nexin-1 conformational single domain antibodies and uses thereof
EP3997225A1 (en) 2019-07-10 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of epilepsy
WO2021007515A1 (en) 2019-07-11 2021-01-14 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with micrornas and other factors
JP7753184B2 (ja) 2019-07-16 2025-10-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Ｃｄ３８に特異性を有する抗体及びその使用
WO2021009299A1 (en) 2019-07-17 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
US20220281967A1 (en) 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
EP4022637A2 (en) 2019-08-30 2022-07-06 Juno Therapeutics, Inc. Machine learning methods for classifying cells
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
EP4025206A1 (en) 2019-09-02 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating pax6- deficiency related disease
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
EP4025604A1 (en) 2019-09-04 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies specific for il20-rb and uses thereof for the treatment of acute exacerbation of chronic obstructive pulmonary disease
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021048171A1 (en) 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2021055801A1 (en) 2019-09-18 2021-03-25 The Medical College Of Wisconsin, Inc. Improved alpha-galactosidase protein for enzyme replacement therapy (ert) and methods of use
AU2020356334A1 (en) 2019-09-24 2022-03-31 Université Catholique de Louvain Modified vesicular stomatitis virus glycoprotein and uses thereof for the treatment of brain tumors
CN114450304B (zh) 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
WO2021058795A2 (en) 2019-09-27 2021-04-01 Stark Labs Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
JP7640538B2 (ja) 2019-10-08 2025-03-05 トラスティーズ オブ ボストン カレッジ 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
CA3154281A1 (en) 2019-10-16 2021-04-22 Andrew Scharenberg Retroviral vector for universal receptor therapy
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
CN115087868A (zh) 2019-11-05 2022-09-20 朱诺治疗学股份有限公司 确定治疗性t细胞组合物的属性的方法
CA3160178A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
WO2021099394A1 (en) 2019-11-19 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Antisense oligonucleotides and their use for the treatment of cancer
JP2023502712A (ja) 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
IL293116A (en) 2019-11-25 2022-07-01 Univ Cornell apoe gene therapy
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021113770A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
US12577324B2 (en) 2019-12-09 2026-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity to HER4 and uses thereof
CN114981299A (zh) 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
JP2023525423A (ja) 2020-01-15 2023-06-16 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
EP4093752A2 (en) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimeric polypeptides
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
KR20220145341A (ko) 2020-01-24 2022-10-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 여포성 림프종 및 변연부 림프종의 투여 및 치료 방법
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
CN115697388A (zh) 2020-01-30 2023-02-03 优莫佳生物制药股份有限公司 双特异性转导增强子
KR20220137009A (ko) 2020-02-04 2022-10-11 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 염증 질환을 치료하기 위한 방법 및 약제학적 조성물
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
CN115427555A (zh) 2020-02-28 2022-12-02 武田药品工业株式会社 由多能干细胞产生自然杀伤细胞的方法
CA3173567A1 (en) 2020-03-02 2021-09-10 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed micrornas
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN115768899B (zh) 2020-03-09 2026-03-27 詹森生物科技公司 用于定量重组载体核酸整合的组合物和方法
CA3173527A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
CA3171066A1 (en) 2020-03-11 2021-09-16 Saar GILL Methods and composition for gene delivery using an engineered viral particle
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
US20210322471A1 (en) 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4127144A1 (en) 2020-03-31 2023-02-08 Sana Biotechnology, Inc. Targeted lipid particles and compositions and uses thereof
AU2021248679A1 (en) 2020-04-02 2022-10-27 Takeda Pharmaceutical Company Limited ADAMTS13 variant, compositions, and uses thereof
CN115667289A (zh) 2020-04-10 2023-01-31 索拉生物科学有限公司 用于治疗蛋白聚集障碍的组合物和方法
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
CA3181339A1 (en) 2020-04-27 2021-11-04 Juno Therapeutics, Inc. Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity
WO2021222168A2 (en) 2020-04-28 2021-11-04 Sola Biosciences Llc Compositions and methods for the treatment of tdp-43 proteinopathies
KR20230008751A (ko) 2020-05-12 2023-01-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
WO2021231657A1 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
IL298558A (en) 2020-05-27 2023-01-01 Antion Biosciences Sa Adapter molecules redirect CAR T cells to the antigen of interest
BR112022024064A2 (pt) 2020-05-29 2023-01-31 Fujifilm Cellular Dynamics Inc Bicamada de epitélio pigmentado da retina e fotorreceptores e uso dos mesmos
PH12022552993A1 (en) 2020-05-29 2023-01-16 Fujifilm Cellular Dynamics Inc Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
WO2021248038A1 (en) 2020-06-05 2021-12-09 Sola Biosciences Llc Compositions and methods for the treatment of synucleinopathies
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
WO2021263070A1 (en) 2020-06-26 2021-12-30 Csl Behring Llc Donor t-cells with kill switch
CN115884986A (zh) 2020-06-29 2023-03-31 Inserm(法国国家健康医学研究院) 抗蛋白s单域抗体和包含其的多肽
KR20230033647A (ko) 2020-06-30 2023-03-08 멘두스 비.브이. 난소암 백신에서 백혈병 유래 세포의 용도
IL299771A (en) 2020-07-10 2023-03-01 Inst Nat Sante Rech Med Methods and compounds for the treatment of epilepsy
CN116323656A (zh) 2020-07-16 2023-06-23 优莫佳生物制药股份有限公司 门控衔接子靶向受体
IL300263A (en) 2020-08-07 2023-03-01 Spacecraft Seven Llc Plakophilin-2 (PKP2) gene therapy using an AAV vector
US20260028412A1 (en) 2020-08-10 2026-01-29 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
WO2022036068A1 (en) 2020-08-13 2022-02-17 A2 Biotherapeutics, Inc. Gene fusions for control of genetically modified cells
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
MX2023002330A (es) 2020-09-04 2023-03-21 Merck Patent Gmbh Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
JP7415042B2 (ja) 2020-10-09 2024-01-16 テナヤ セラピューティクス， インコーポレイテッド プラコフィリン２遺伝子治療の方法および組成物
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
WO2022087453A1 (en) 2020-10-22 2022-04-28 Lyell Immunopharma, Inc. Chimeric activation receptors
CA3199433A1 (en) 2020-10-26 2022-05-05 Sola Biosciences Llc Compositions and methods for the treatment of alzheimer's disease
EP4232070A1 (en) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Methods of inducing stem cell mobilization
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
JP2023550309A (ja) 2020-11-04 2023-12-01 セルジーン コーポレーション 以前に抗がんアルキル化剤療法を受けた患者におけるｃａｒ ｔ細胞療法
CN116615236A (zh) 2020-11-05 2023-08-18 新免疫技术有限公司 用il-7蛋白和核苷酸疫苗的组合治疗肿瘤的方法
WO2022097068A1 (en) 2020-11-05 2022-05-12 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
US12564642B2 (en) 2020-11-10 2026-03-03 Sanofi CEACAM5 antibody-drug conjugate formulation
KR20230107260A (ko) 2020-11-12 2023-07-14 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
EP4272002A1 (en) 2020-12-04 2023-11-08 Celgene Corporation Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
CA3202176A1 (en) 2020-12-14 2022-06-23 Michael Steven ROONEY Tissue-specific antigens for cancer immunotherapy
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
US20240131138A1 (en) 2020-12-23 2024-04-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
CA3204161A1 (en) 2021-01-11 2022-07-14 Jagesh Vijaykumar SHAH Use of cd8-targeted viral vectors
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
US20250282870A1 (en) 2021-01-20 2025-09-11 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
AU2022211682A1 (en) 2021-01-22 2023-08-03 Mendus B.V. Methods of tumor vaccination
MX2023008831A (es) 2021-01-27 2023-10-19 Umoja Biopharma Inc Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19.
EP4284832A1 (en) 2021-01-29 2023-12-06 (INSERM) Institut National de la Santé et de la Recherche Médicale Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
CN118638226A (zh) 2021-03-19 2024-09-13 葛兰素史密斯克莱知识产权发展有限公司 靶向密蛋白3的嵌合抗原受体和治疗癌症的方法
KR20230158573A (ko) 2021-03-22 2023-11-20 주노 쎄러퓨티크스 인코퍼레이티드 바이러스 벡터 입자의 효력을 평가하는 방법
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
WO2022200469A1 (en) 2021-03-24 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) A dominant negative protein of rad51 for treating cancer
WO2022212400A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
EP4322937A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve the anti-tumoral activity of macrophages
US20240228659A1 (en) 2021-04-14 2024-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
AU2022257093A1 (en) 2021-04-16 2023-11-02 Celgene Corporation T cell therapy in patients who have had prior stem cell transplant
CA3217028A1 (en) 2021-04-22 2022-10-27 Baylor College Of Medicine Methods of engineering immune cells having reduced fratricidal activity
CA3217862A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
US20240238385A1 (en) 2021-05-13 2024-07-18 Universidade Do Algarve Isolated or artificial nucleotide sequences for use in neurodegenerative diseases
US20240228987A1 (en) 2021-05-26 2024-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Hexokinase-derived peptides and therapeutical uses thereof
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2022251712A1 (en) 2021-05-28 2022-12-01 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
JP2024520676A (ja) 2021-06-02 2024-05-24 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３欠損免疫細胞及びその使用
US20240141001A1 (en) 2021-06-14 2024-05-02 Institut National de la Santé et de la Recherche Médicale Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2022264033A1 (en) 2021-06-15 2022-12-22 Takeda Pharmaceutical Company Limited Method for producing natural killer cells from pluripotent stem cells
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
JP2024529467A (ja) 2021-07-27 2024-08-06 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｃｔ４５に特異的に結合する抗原結合タンパク質
US20250084420A1 (en) 2021-08-02 2025-03-13 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
EP4130038A1 (en) 2021-08-03 2023-02-08 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Anti-il-2 antibody, complex comprising it, and uses thereof
US20240344083A1 (en) 2021-08-04 2024-10-17 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
JP2024531234A (ja) 2021-08-11 2024-08-29 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法のための遺伝子改変された初代細胞
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
JP2024534771A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
GB202112471D0 (en) 2021-09-01 2021-10-13 King S College London Microna systems
EP4408874A1 (en) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
EP4413024A2 (en) 2021-10-08 2024-08-14 SOLA Biosciences LLC Compositions and methods for the treatment of proteopathies
CA3234720A1 (en) 2021-10-08 2023-04-13 Sola Biosciences Llc Compositions and methods for the treatment of p53-mediated cancers
US20250230511A1 (en) 2021-10-29 2025-07-17 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
AU2022386716A1 (en) 2021-11-15 2024-05-02 Technische Universität Dresden Site-specific recombinases for efficient and specific genome editing
EP4433504A1 (en) 2021-11-17 2024-09-25 Institut National de la Santé et de la Recherche Médicale Universal sarbecovirus vaccines
EP4433512A4 (en) 2021-11-19 2025-12-31 Univ Pennsylvania Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy
US20250002596A1 (en) 2021-12-01 2025-01-02 Institut National de la Santé et de la Recherche Médicale Neutralizing anti-cd95l monoclonal antibodies
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
US20250051755A1 (en) 2021-12-17 2025-02-13 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
JP2025500894A (ja) 2021-12-17 2025-01-15 ウモジャ バイオファーマ インコーポレイテッド 細胞傷害性自然リンパ球系細胞およびその使用
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
EP4456907A1 (en) 2021-12-30 2024-11-06 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4209508A1 (en) 2022-01-11 2023-07-12 Centre national de la recherche scientifique Nanobodies for the deneddylating enzyme nedp1
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
JP2025504081A (ja) 2022-02-01 2025-02-06 コーネル・ユニバーシティー フリードライヒ運動失調症に関連する心筋症の治療及び予防のための方法及び医薬組成物
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
US20250066471A1 (en) 2022-02-16 2025-02-27 Institut National de la Santé et de la Recherche Médicale Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
JP2025508720A (ja) 2022-02-17 2025-04-10 サナ バイオテクノロジー，インコーポレイテッド 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照
WO2023161412A1 (en) 2022-02-25 2023-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for preventing the cleavage of cd95l by metalloproteases
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
CN119487076A (zh) 2022-03-09 2025-02-18 默克专利股份公司 抗ceacam5抗体及其缀合物和用途
US20250255902A1 (en) 2022-03-09 2025-08-14 Dana-Farber Cancer Institute, Inc. Genetically engineered b cells and methods of use thereof
JP2025510588A (ja) 2022-03-11 2025-04-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ細胞及びｔ細胞を特異的に初期化するための核酸系及びその使用
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
AU2023236826A1 (en) 2022-03-18 2024-09-26 The Regents Of The University Of Colorado, A Body Corporate Genetically engineered t-cell co-receptors and methods of use thereof
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
CN119365208A (zh) 2022-04-13 2025-01-24 巴塞罗那自治大学 通过表达klotho蛋白的基因疗法治疗神经肌肉疾病
GB202206507D0 (en) 2022-05-04 2022-06-15 Antion Biosciences Sa Expression construct
US20250223326A1 (en) 2022-05-10 2025-07-10 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
KR20250011945A (ko) 2022-05-17 2025-01-22 우모자 바이오파마 인코포레이티드 바이러스 입자의 제조
JP2025521120A (ja) 2022-05-18 2025-07-08 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
IL317172A (en) 2022-05-26 2025-01-01 Regeneron Pharma Lentiviral vector maintenance vehicles and uses thereof
WO2023237663A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
IL317532A (en) 2022-06-10 2025-02-01 Umoja Biopharma Inc Engineered stem cells and their uses
US20260053913A1 (en) 2022-06-10 2026-02-26 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
EP4551711A1 (en) 2022-07-08 2025-05-14 Cornell University Methods and pharmaceutical compositions for the treatment and the prevention of alzheimers disease
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
EP4558128A1 (en) 2022-07-21 2025-05-28 Institut National de la Santé et de la Recherche Médicale Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
CN119866224A (zh) 2022-07-28 2025-04-22 加拿大干细胞技术公司 编码连接抗原的多核苷酸以及其用途
KR20250050869A (ko) 2022-08-15 2025-04-15 에프. 호프만-라 로슈 아게 재조합 바이러스 벡터와 관련된 부작용의 예방 또는 완화
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4580658A1 (en) 2022-08-31 2025-07-09 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
EP4583905A1 (en) 2022-09-06 2025-07-16 Institut National de la Santé et de la Recherche Médicale Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
JP2025531832A (ja) 2022-09-08 2025-09-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＬＴＢＰ２（潜在的形質転換増殖因子β結合タンパク質２）に対する特異性を有する抗体及びその使用
CN120225559A (zh) 2022-09-12 2025-06-27 国家健康与医学研究院 新型抗itgb8抗体及其用途
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
EP4598953A1 (en) 2022-10-05 2025-08-13 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024079317A1 (en) 2022-10-14 2024-04-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies
PT118269A (pt) 2022-10-20 2024-04-22 Univ Aveiro Pkmyt1 for use in regenerative medicine
AU2023371650A1 (en) 2022-11-04 2025-05-29 Umoja Biopharma, Inc. Polynucleotide construct and related viral vectors and methods
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
KR20250121163A (ko) 2022-11-04 2025-08-11 우모자 바이오파마 인코포레이티드 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
CN120752339A (zh) 2023-01-06 2025-10-03 国家医疗保健研究所 静脉内施用用于治疗疼痛的反义寡核苷酸
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
EP4658303A1 (en) 2023-02-02 2025-12-10 Institut National de la Santé et de la Recherche Médicale Anti-tuberculosis vaccine targeting selected mycobacterium tuberculosis protective antigens to dendritic cells
WO2024170500A1 (en) 2023-02-13 2024-08-22 Institut National de la Santé et de la Recherche Médicale Methods of treating iron deficiency-related diseases
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
WO2024175604A1 (en) 2023-02-21 2024-08-29 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of sanfilippo syndrome type iiib
US20240342313A1 (en) 2023-03-30 2024-10-17 Pharma Cinq, Llc Vector encoding rod-derived cone viability factor and human igk signal sequence
WO2024200846A1 (en) 2023-03-30 2024-10-03 272BIO Limited Gnrh-binding polypeptides and uses thereof
WO2024209036A1 (en) 2023-04-07 2024-10-10 Institut National de la Santé et de la Recherche Médicale Generating highly pure glutamatergic neuronal populations using the pro-neural factor ascl1
WO2024213767A1 (en) 2023-04-14 2024-10-17 Institut National de la Santé et de la Recherche Médicale Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
EP4698902A1 (en) 2023-04-18 2026-02-25 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024258754A1 (en) 2023-04-18 2025-11-13 Cornell University Methods and apoe pharmaceutical compositions for the treatment and the prevention of alzheimers disease
WO2024220719A1 (en) 2023-04-18 2024-10-24 Crystal Ronald G Modified aav capsids for gene delivery
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220722A1 (en) 2023-04-18 2024-10-24 Cornell University Compositions and methods for tissue- specific expression of gene therapies
EP4698215A1 (en) 2023-04-19 2026-02-25 GlaxoSmithKline Intellectual Property Development Limited Cytotoxicity targeting chimeras for car-t and car-nk cells
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
GB202306619D0 (en) 2023-05-04 2023-06-21 Antion Biosciences Sa Cell
WO2024231820A1 (en) 2023-05-05 2024-11-14 Takeda Pharmaceutical Company Limited Treatment of pompe disease
WO2024238153A1 (en) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
EP4716851A2 (en) 2023-05-23 2026-04-01 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
EP4724809A2 (en) 2023-06-08 2026-04-15 Cornell University Satseq: a modular system for coupling saturation mutagenesis, dna barcoding, and deep sequencing
EP4731681A1 (en) 2023-06-23 2026-04-29 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2025004002A2 (en) 2023-06-30 2025-01-02 Takeda Pharmaceutical Company Limited Treatment of pompe disease
KR20260033048A (ko) 2023-07-03 2026-03-10 네오이뮨텍, 인코퍼레이티드 이종이합체 fc 분자 및 이의 용도
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025017186A1 (en) 2023-07-20 2025-01-23 Institut National de la Santé et de la Recherche Médicale Extracellular vesicles functionalized with a tethering system for cargo delivery
WO2025021839A1 (en) 2023-07-25 2025-01-30 Institut National de la Santé et de la Recherche Médicale Method to treat metabolic disorders
AU2024300235A1 (en) 2023-07-27 2026-01-08 Immatics Biotechnologies Gmbh Antigen binding proteins against mageb2
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025032112A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of type 2-mediated diseases
WO2025045915A1 (en) 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025059113A1 (en) 2023-09-12 2025-03-20 The Board Of Regents Of The University Of Oklahoma Treatments for enhancing immune response to clostridioides difficile infections
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
US20250152714A1 (en) 2023-11-15 2025-05-15 Immusoft Corporation Migratory modified differentiated b cells for cancer therapy
WO2025104700A2 (en) 2023-11-16 2025-05-22 Takeda Pharmaceutical Company Limited Improved methods for cryopreservation and fitness of natural killer cells, and compositions thereof
EP4563586A1 (en) 2023-11-28 2025-06-04 Université Paris Cité New inhibitors of lrrk2/pp1 interaction
WO2025114512A1 (en) 2023-11-29 2025-06-05 Cnrs Dsi Therapeutic use of surf2 modulators
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025125363A1 (en) 2023-12-11 2025-06-19 Institut National de la Santé et de la Recherche Médicale Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
WO2025129084A1 (en) 2023-12-13 2025-06-19 Umoja Biopharma, Inc. Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
WO2025132560A1 (en) 2023-12-19 2025-06-26 Institut National de la Santé et de la Recherche Médicale Methods of treating cancer combining uros invalidation and phototherapy
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation
WO2025147573A2 (en) 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease
WO2025153530A1 (en) 2024-01-16 2025-07-24 Novo Nordisk A/S Albumin-targeted endonucleases, compositions, and methods of use
WO2025157848A1 (en) 2024-01-23 2025-07-31 Institut National de la Santé et de la Recherche Médicale Methods for the intravenous treatment of sanfilippo syndrome type iiib
WO2025171001A1 (en) 2024-02-06 2025-08-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for improved production of aav viral vectors
GB202402745D0 (en) 2024-02-27 2024-04-10 Antion Biosciences Sa Cell
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025186293A1 (en) 2024-03-06 2025-09-12 Institut National de la Santé et de la Recherche Médicale Chmp2b mutants for use for treating infection
WO2025202674A1 (en) 2024-03-27 2025-10-02 Institut National de la Santé et de la Recherche Médicale Langerhans cells targeting hiv-1 vaccines
WO2025215206A1 (en) 2024-04-12 2025-10-16 Institut National de la Santé et de la Recherche Médicale Activator of primary cilia to treat cognitive dysfunctions or ciliopathies
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025233432A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025247918A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247913A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Anti-ifn-omega1 monoclonal antibodies
WO2025247924A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247917A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 AND ANTI-IFN-ω1 MONOCLONAL ANTIBODIES
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025252857A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale Il-15 muteins with ph-dependent binding for il-15ralpha
WO2025252855A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
US20250388676A1 (en) 2024-06-20 2025-12-25 Sanofi Binding proteins comprising an anti-immune checkpoint antibody or a fragment thereof and single-chain tnfrsf ligand multimers
WO2026002973A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Host immune cells engineered to overexpress a foxk1 polypeptide
WO2026006832A1 (en) 2024-06-28 2026-01-02 University Of Connecticut Gene modulation for treating cancer
WO2026003242A1 (en) 2024-06-28 2026-01-02 Institut National de la Santé et de la Recherche Médicale Dendritic cells-targeting vaccine against hbv infection
WO2026033259A1 (en) 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders
WO2026033136A1 (en) 2024-08-09 2026-02-12 Immatics Biotechnologies Gmbh Advanced treatment modalities for anti-prame tcr-engineered immune cells
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators
GB202415862D0 (en) 2024-10-28 2024-12-11 Antion Biosciences Sa Intronic mirna

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
JPH05501201A (ja) * 1989-10-16 1993-03-11 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 非感染性ｈｉｖ―１粒子およびそれらの使用
WO1991019798A1 (en) * 1990-06-20 1991-12-26 Dana Farber Cancer Institute Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
CA2557882C (en) * 1992-02-28 2010-05-18 Syngenix Limited Defective packaging non-oncoviral vectors based on mpmv and hiv
AU678152B2 (en) * 1992-03-27 1997-05-22 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
DE69430646T2 (de) * 1993-02-17 2003-01-02 Wisconsin Alumni Research Foundation, Madison Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5580766A (en) * 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
JPH09510361A (ja) * 1994-03-24 1997-10-21 シンジェニックス・リミテッド パッケージング欠陥性レンチウイルス
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines

Also Published As

Publication number Publication date
JP4190579B2 (ja) 2008-12-03
IL123833A0 (en) 1998-10-30
EP0871459A1 (en) 1998-10-21
AU7168196A (en) 1997-04-28
ATE260981T1 (de) 2004-03-15
DE69631795D1 (de) 2004-04-08
AU720993B2 (en) 2000-06-22
DE69631795T2 (de) 2005-02-10
JPH11512615A (ja) 1999-11-02
EP0871459B1 (en) 2004-03-03
WO1997012622A1 (en) 1997-04-10
US6013516A (en) 2000-01-11
EP0871459A4 (en) 2001-09-05

Similar Documents

Publication Publication Date Title
IL123833A0 (en) Vector and method of use for nucleic acid delivery to non-dividing cells
AU4880093A (en) Retrovirus from the HIV group and its use
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
GB2193499B (en) Process for the genetic modification of yeast
FR2681786B1 (enExample)
WO1998039463A3 (en) Lentivirus based vector and vector system
DE69032841D1 (de) Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
GB2331522A (en) Lentiviral vectors
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
AU599091B2 (en) Expression and purification of an htlv-iii gag/env gene protein
EP0226448A3 (en) Solubilisation of protein aggregates
EP0815125A4 (en) gC1q RECEPTOR, BINDING HIV-1 gp120 REGION, RELATED PEPTIDES AND ANTIBODIES
EP0219106A3 (en) Polypeptides that elicit antibodies against aids virus
CA2185712A1 (en) Enhanced virus-mediated dna transfer
WO1998011243A3 (en) Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein
EP1686181A3 (en) Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains
ES2010727A6 (es) Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv.
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
DE69706592D1 (de) Verfahren zur Herstellung von positivelektrode-aktivem Material, sowie diese verwendende nichtwässerige Sekundärbatterie
EP0252392A3 (en) Viral inactivation and purification of active proteins
AU2157888A (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
IL122119A0 (en) Encapsulated cells producing viral particles
HU895788D0 (en) Process for producing peptides and medical products containing them
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
DE3750348D1 (de) Verfahren zur Herstellung von Peptiden, dazu zu verwendendes rekombinantes Plasmid und mit diesem Plasmid transformierte Myelomzellen.